Pharmacokinetic analysis of vilobelimab, anaphylatoxin C5a and antidrug antibodies in PANAMO: a phase 3 study in critically ill,  invasively mechanically ventilated COVID-19 patients

Pharmacokinetic analysis of vilobelimab, anaphylatoxin C5a and antidrug antibodies in PANAMO: a phase 3 study in critically ill,  invasively mechanically ventilated COVID-19 patients

Abstract Background Vilobelimab, a complement 5a (C5a)-specific monoclonal antibody, reduced mortality in critically ill COVID-19 patients in a phase 3 multicentre, randomized, double-blind, placebo-controlled study. As part of the study, vilobelimab concentrations and C5a levels as well as antidrug...

Full description

Bibliographic Details
Main Authors: Endry H. T. Lim, Alexander P. J. Vlaar, Sanne de Bruin, Simon Rückinger, Claus Thielert, Maria Habel, Renfeng Guo, Bruce P. Burnett, James Dickinson, Matthijs C. Brouwer, Niels C. Riedemann, Diederik van de Beek, the PANAMO study group
Format: Article
Language:English
Published: SpringerOpen 2023-06-01
Series:Intensive Care Medicine Experimental
Subjects:
PK
Pharmacokinetic
C5a
Complement
Vilobelimab
ADA
Online Access:https://doi.org/10.1186/s40635-023-00520-8

Similar Items

Similar Items